update on pi3k inhibitors for cll: idelalisib, copanlisib, duvelisib, and umbralisib
Published 5 years ago • 1.6K plays • Length 18:36Download video MP4
Download video MP3
Similar videos
-
3:40
pi3k inhibitors for cll
-
21:19
other new molecules in the cll pipeline: pi3k inhibitors, syk inhibitors, etc.
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
25:24
pi3k inhibitors in cll and lymphoma
-
1:41
the role of pi3k inhibitors in cll
-
3:46
pi3k inhibitors in management of cll
-
17:28
role of pi3k inhibitors in clinical practice: uses and pitfalls
-
2:01
safety data for the pi3kδ inhibitor umbralisib for lymphoid malignancies
-
21:42
update on btk inhibitors for cll: ibrutinib pus the new kids on the block: are they better?
-
3:59
role of pi3k inhibitors in treatment of b-cell malignancies
-
7:10
the use of novel pi3k inhibitors in cll
-
12:59
cll: idelalisib based regimens
-
14:48
cll: update on approved tkis
-
2:55
umbralisib for cll patients intolerant to btk inhibitors
-
3:41
future of pi3k inhibition in fl and cll
-
0:53
dr. abedin on pi3k inhibitors in cll
-
1:46
tgr-1202- a new generation pi3k delta inhibitor for cll
-
1:06
dr. smith on pi3k inhibitors in cll
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?